

30 Apr 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: BMS names new CEO; Novartis culls pipeline; AstraZeneca taps Chinese innovation; Q2 approvals to look out for; and a look at deal-making trends in 2022.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 April 2023, including: [Bristol Myers Squibb Company](#) names new CEO; [Novartis AG](#) culls pipeline; [AstraZeneca PLC](#) taps Chinese innovation; Q2 approvals to look out for; and a look at deal-making trends in 2022.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Bristol's Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight](#)" - Scrip, 26 Apr, 2023.)

(Also see "[Novartis Culls Pipeline As 'Pure-Play' Drive Progresses](#)" - Scrip, 25 Apr, 2023.)

(Also see "[AstraZeneca Oncology R&D Head On China Biotech Innovation](#)" - Scrip, 20 Apr, 2023.)

(Also see "[10 Approvals To Look Out For In Q2](#)" - Scrip, 20 Apr, 2023.)

(Also see "[2022 Deal-Making Snapshot: One Big Deal Didn't Change The Downward Trends](#)" - Scrip, 21 Apr, 2023.)

[Click here to explore this interactive content online](#) 